The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

From Washington to Wall Street, it's a crazy time for biotech. But as Ultragenyx Pharmaceutical Inc. celebrates its 15th ...

The South San Francisco biotech has acquired rights to tralesinidase alfa, an enzyme replacement therapy (ERT) for the ...

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

After dropping development in December of its lead program, Spruce Biosciences Inc. has found new life by acquiring a BLA-ready enzyme replacement therapy for the rare genetic neurodegenerative ...

Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.

Zacks Equity Research shares Astronics ATRO as the Bull of the Day and The Boston Beer Company SAM as the Bear of the Day ...

Donald Trump's tariffs threaten to decimate Ireland's pharmaceutical industry as the US President seeks to "force" companies ...

BioMarin Pharmaceutical (BMRN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Viridian Therapeutics, Inc. (NASDAQ: VRDN) has announced the appointment of Jeff Ajer to its board of directors. Ajer, who ...